Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Duchenne Muscular Dystrophy Treatment Market: By Drug Class By Distribution Channel and Geography
Duchenne Muscular Dystrophy Treatment Market: By Drug Class By Distribution Channel and Geography
Duchenne Muscular Dystrophy Treatment Market size was estimated at US$ 3.8 Bn in 2022, growing at a CAGR of 38.2% from 2023-2029. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne Awareness Day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the World's Duchenne Awareness Day. In 2015, U.S. FDA published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for drugs such as ezutromid of summit therapeutics a phase II clinical trial drug that received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.
Study Period
2024-2030Base Year
2023CAGR
38.2%Largest Market
EuropeFastest Growing Market
North America
Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of Market. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in the UK, while 349 new cases were reported in the U.S. in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about Duchenne muscular dystrophy is also propelling the growth of the Market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of Duchenne muscular dystrophy.
On the basis of geographical regions, Duchenne Muscular Dystrophy Treatment Market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. The European region is the dominating market in global DMD treatment market owing to the several treatments for DMD which are approved and are under review in EU. For instance, PTC Therapeutics has recently received orphan drug designation and conditional approval for its Translarna, a gene therapy to treat DPD. North America holds a significant position in DMD treatment market owing to the high prevalence of DMD. Emerging markets like Asia Pacific, Latin America are expected to have significant growth rate owing to the growing prevalence of DMD, large patient pool and growing healthcare expenditure and awareness of DMD.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
38.2% |
|
By Drug Class |
|
|
By Distribution Channel |
|
|
By Region |
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa (MEA)
|
Download Free Sample Report
The duchenne muscular dystrophy treatment market was valued at US$ 3.8 billion in 2022
The duchenne muscular dystrophy treatment market key players are: Bristol-Myers Squibb(U.S) FibroGen, Inc (U.S) ITALFARMACO S.p.A. (Italy) Catabasis Pharmaceuticals, Inc.(U.S) NS Pharma, Inc. (U.S) Marathon Pharmaceuticals, LLC (U.S) ReveraGen BioPharma, Inc. (U.S) Pfizer (U.S) Summit Therapeutics plc (U.K) Taiho Pharmaceutical Co (Japan) Sarepta Therapeutics, Inc. (U.S) Santhera Pharmaceuticals PTC Therapeutics (Switzerland)
The duchenne muscular dystrophy treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.